Doctors begin new clinical trial treating cancer with 70p malaria drug

March 8, 2017, St. George's University of London
Doctors begin new clinical trial treating cancer with 70p malaria drug
Credit: St George's University of London

Experts from St George's University of London, and St George's Hospital have joined forces to investigate whether a common and cheap malaria drug can be used also against cancer.

The researchers and clinicians raised more than £50,000 through a campaign to fund the second part of their trial into whether the drug artesunate can tackle colorectal cancer and now are recruiting patients to take part in their clinical studies.

In all £54,247 was raised through crowd funding to investigate whether the drug can help by reducing the multiplication of tumour cells and decreasing the risk of cancer spreading or recurring after surgery.

If it does the drug could be used to provide a cheaper adjunct to current expensive chemotherapy.

Professor Sanjeev Krishna, an infectious disease expert at St George's, University of London, who jointly leads the study with Professor Devinder Kumar, a colorectal cancer surgeon based at St George's Hospital, said: "We are delighted that the next phase of our study is now going ahead and we are looking forward to working with patients to examine whether this important work can have a real impact on cancer patients' lives.

"Working with colleagues at St George's Hospital has proved invaluable. Our partnerships will now also include Ashford and St Peter's University Hospitals and Kingston University Hospital NHS Foundation Trusts so we can speed up the process of recruiting patients and getting the study results.

"Collaborations like this between the academic researchers and clinicians in our leading hospitals are the bedrock of our opportunities to gain understanding and potential breakthroughs in treatment that can benefit many.

"Other centres are also welcome to join if interested in our work, which is now moving into answering the clinically important questions aiming to change practice."

Researchers worked with supporters from the public, patients, colleagues and charities including Bowel Disease UK and the AntiCancer Fund to support their crowdfunding campaign on FutSci, an organisation that aims to support crowdfunding for research, innovation and technology in the life sciences.

A charity, Bowel Disease UK, started by Gary Douch after he became a patient treated by Professor Kumar donated £200,000 to fund the study.

Professor Devinder Kumar, who has been a colorectal cancer surgeon for three decades, added: "We are proud to have set up this pioneering study at St George's University and St George's University Hospitals NHS Foundation Trust. We hope that this study will help to answer some really important research questions to see if a simple intervention with an established, off patent and affordable antimalarial drug such as artesunate taken for 2 weeks before surgery can reduce the risk of cancer recurrence in patients with Stage II/III bowel cancer. The overall aim of our research is to improve patient survival and quality of life. Research into repurposing drugs in this way for new disease indications is vital and an excellent use of resources for the NHS."

Artesunate is derived from the plant Artemisia annua also known as Sweet Wormwood. The Chinese scientist Tu Youyou whose research in the 1960s led to the development of artesunate from a plant used in Chinese traditional medicine, was awarded the Nobel Prize for Medicine 2015.

More than one million patients are diagnosed with globally each year. Colorectal cancer is the third most common cancer in men and the second most common cancer in women and is a leading cause of mortality. In the UK, 110 new cases are diagnosed daily, with older patients particularly at risk of death. Current treatments involve complex combinations of surgery, chemotherapy and radiotherapy.

Explore further: Crowd funding bid to test whether malaria drug kills cancer

Related Stories

Crowd funding bid to test whether malaria drug kills cancer

October 16, 2015
Medical experts investigating whether a common malaria drug could have a significant impact on colorectal cancer have launched a crowd funding project to fund their work.

Cheap malaria drug could treat colorectal cancer effectively too, say experts

November 18, 2014
Medical experts say a common malaria drug could have a significant impact on colorectal cancer providing a cheap adjunct to current expensive chemotherapy.

Specific immune cells predict bowel cancer outcomes

March 6, 2017
A pilot study by University of Otago researchers suggests that people with colorectal cancer that have a certain type of immune cell in their tumour may have increased survival rates.

Researcher finds key to drug resistant bowel cancer

November 8, 2016
Blocking a molecule could bypass bowel cancer's defence against the drug cetuximab, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

Drug that helps addicts may help treat cancer too, say experts

June 28, 2016
Scientists at St George's, University of London, say the drug naltrexone (LDN), which is used to treat addicts, can have a beneficial impact on cancer patients if it is given in low doses.

Pancreatic cancer set to become third biggest cancer killer in EU next year

November 7, 2016
The number of deaths from pancreatic cancer will overtake breast cancer mortality rates in the EU in 2017, a study has found.

Recommended for you

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

NEJM reports positive results for larotrectinib against TRK-fusion cancer

February 22, 2018
In 2013, the labs of University of Colorado Cancer Center investigator Robert C. Doebele, MD, PhD, and Dana-Farber Cancer Institute investigator Pasi A. Jänne, MD, PhD reported in Nature Medicine the presence of TRK gene ...

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

New therapeutic gel shows promise against cancerous tumors

February 21, 2018
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results ...

Five novel genetic changes linked to pancreatic cancer risk

February 21, 2018
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and collaborators from over 80 other ...

Similarities found in cancer initiation in kidney, liver, stomach, pancreas

February 21, 2018
Recent research at Washington University School of Medicine in St. Louis demonstrated that mature cells in the stomach sometimes revert back to behaving like rapidly dividing stem cells. Now, the researchers have found that ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.